Ocrelizumab in patients with Primary Progressive Multiple Sclerosis
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To investigate the efficacy of ocrelizumab
compared with placebo in patients with primary progressive multiple sclerosis
Who is Eligible to Participate?
Patients 18-55 years of age diagnosed
with PPMS. Patients must have an EDSS of 3.0-6.5 at screening. Patients
who have received any previous B-cell targeting therapies are ineligible.
Must be off any beta interferon therapy 12 weeks prior to randomization.
Patients must also meet all other inclusion and exclusion criteria explained
in detail by study coordinator.
What is involved in this Study?
Patients will be randomized to a 2:1
treatment fashion to either ocreilizumab or placebo. Patients will have
EDSS scores evaluated and MRIs completed over the course of the study
How long is the Study?
All patients will undergo 24 weeks of study treatment.
The total study duration is approximately 120weeks.
For More Information Contact: Lynne E. Flynn, CCRC, study coordinator,
at 602-258-2863 or lynneflynn@pnal.net or call the Main line at 602-258-3354
